




RealRate

# REAL ESTATE 2014

## HH Biotechnology Holdings CO Rank 41 of 61





RealRate

# REAL ESTATE 2014

## HH Biotechnology Holdings CO Rank 41 of 61

The relative strengths and weaknesses of HH Biotechnology Holdings CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HH Biotechnology Holdings CO compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 26% points. The greatest weakness of HH Biotechnology Holdings CO is the variable Liabilities, Current, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 58%, being 32% points below the market average of 89%.

Input Variable	Value in 1000 USD
Cost of Revenue	5,047
Depreciation and Amortization	19
General and Administrative Expense	1,829
Goodwill and Intangible Assets	0
Lease Income	5,580
Liabilities, Current	35,543
Liabilities, Long-term	0
Other Assets	59,555
Other Compr. Net Income	707
Other Expenses	1,457
Other Liabilities	0
Other Net Income	957
Other Real Estate Investments, Net	0
Other Revenues	0
Real Estate Investment Property, Accumulated Depreciation	0
Real Estate Investment Property, at Cost	0

Output Variable	Value in 1000 USD
Real Estate Investments, Net	0
Liabilities	35,543
Assets	59,555
Revenues	5,580
Expenses	8,351
Stockholders Equity	24,012
Net Income	-1,814
Comprehensive Net Income	-1,412
BaseVar	57,842
ECR before LimitedLiability	29%
Economic Capital Ratio	58%